You are here

P&T News

July 28

The drug is approved as Lyxumia in more than 60 countries
WatchPAT approved for diagnostic testing on patients as young as 12 years old
Antibody adds to toolkits of biologics manufacturers, regulators
EHRs do not increase inpatient mortality, adverse safety events

July 27

Respondents worry about gene editing and synthetic blood
Risks outweigh benefits in certain patients
Experts find little evidence to support routine screening in adults

July 26

Growing percentage of patients combine drugs without physician’s knowledge
Product is extended-release formulation of Viekira Pak
Pregnant women are at risk of exposure from partners of either gender
Celgene won’t pursue indication for diffuse B-cell lymphoma
Hospitals would receive quality-adjusted pricing for heart attack and bypass care

July 25

New research could help identify at-risk individuals
Agency cites manufacturing concerns
Virological suppression is similar to that of Complera and Atripla
Tramiprosate will target patients with specific genes